tradingkey.logo

tradingkey.logo
怜玢


Bausch + Lomb Corp

BLCO
りォッチリストに远加
16.250USD
+0.220+1.37%
終倀 05/13, 16:00ET15分遅れの株䟡
5.79B時䟡総額
損倱額盎近12ヶ月PER


詳现情報 Bausch + Lomb Corp 䌁業名

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Bausch + Lomb Corpの䌁業情報


䌁業コヌドBLCO
䌚瀟名Bausch + Lomb Corp
䞊堎日May 06, 2022
最高経営責任者「CEO」Saunders (Brenton L)
埓業員数13500
蚌刞皮類Ordinary Share
決算期末May 06
本瀟所圚地520 Applewood Crescent
郜垂VAUGHAN
蚌刞取匕所NASDAQ OMX NASDAQ Basic NYSE
囜Canada
郵䟿番号L4K 4B4
電話番号19082552864
りェブサむトhttps://ir.bausch.com/
䌁業コヌドBLCO
䞊堎日May 06, 2022
最高経営責任者「CEO」Saunders (Brenton L)

Bausch + Lomb Corpの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
100.10K
-13.65%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
88.03K
-13.60%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
78.42K
+2.05%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
60.37K
+13.25%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
100.10K
-13.65%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
88.03K
-13.60%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
78.42K
+2.05%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
60.37K
+13.25%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Apr 6
通貚: USD曎新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
䌚瀟名
収益
比率
Devices
1.92B
37.68%
OTC
1.83B
35.95%
Pharmaceuticals
1.08B
21.19%
Branded and other Generics
243.00M
4.76%
Other revenues
21.00M
0.41%
地域別USD
䌚瀟名
収益
比率
U.S. and Puerto Rico
2.55B
49.91%
Other
777.00M
15.23%
China
358.00M
7.02%
France
246.00M
4.82%
Japan
186.00M
3.65%
他の
988.00M
19.37%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Devices
1.92B
37.68%
OTC
1.83B
35.95%
Pharmaceuticals
1.08B
21.19%
Branded and other Generics
243.00M
4.76%
Other revenues
21.00M
0.41%

株䞻

曎新時刻: Sat, May 9
曎新時刻: Sat, May 9
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Bausch Health Companies Inc
87.07%
Deutsche Bank Securities Inc.
0.99%
Icahn Capital LP
0.98%
Oaktree Capital Management, L.P.
0.95%
D. E. Shaw & Co., L.P.
0.80%
他の
9.22%
株䞻統蚈
株䞻統蚈
比率
Bausch Health Companies Inc
87.07%
Deutsche Bank Securities Inc.
0.99%
Icahn Capital LP
0.98%
Oaktree Capital Management, L.P.
0.95%
D. E. Shaw & Co., L.P.
0.80%
他の
9.22%
皮類
株䞻統蚈
比率
Corporation
87.07%
Hedge Fund
3.96%
Investment Advisor/Hedge Fund
3.36%
Investment Advisor
2.33%
Research Firm
1.66%
Individual Investor
0.57%
Family Office
0.23%
他の
0.83%

機関投資家保有株


曎新時刻: Wed, Apr 1
曎新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q1
249
40.30M
11.30%
-25.01M
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Bausch Health Companies Inc
310.45M
87.43%
--
--
Mar 24, 2025
Deutsche Bank Securities Inc.
3.45M
0.97%
-50.00K
-1.43%
Dec 31, 2025
Icahn Capital LP
3.50M
0.99%
--
--
Dec 31, 2025
Oaktree Capital Management, L.P.
3.38M
0.95%
+137.30K
+4.23%
Dec 31, 2025
D. E. Shaw & Co., L.P.
2.85M
0.8%
+239.63K
+9.19%
Dec 31, 2025
GoldenTree Asset Management, LP
2.66M
0.75%
--
--
Dec 31, 2025
Silver Point Capital, L.P.
2.56M
0.72%
--
--
Dec 31, 2025
Caspian Capital LP
2.00M
0.56%
+1.35M
+207.55%
Dec 31, 2025
Davidson Kempner Capital Management LP
1.94M
0.55%
+959.24K
+97.83%
Dec 31, 2025
Glenview Capital Management, LLC
1.65M
0.47%
+100.00K
+6.44%
Dec 31, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
詳现を芋る
Ballast Small/Mid Cap ETF
比率1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
比率0.03%
BNY Mellon US Small Cap Core Equity ETF
比率0.03%
Schwab Fundamental International Small Equity ETF
比率0%
Goldman Sachs MarketBeta US 1000 Equity ETF
比率0%
Invesco Zacks Mid-Cap ETF
比率0%
QRAFT AI-Enhanced US Large Cap ETF
比率0%
AltShares Event-Driven ETF
比率0%
DFA Dimensional International Core Equity 2 ETF
比率0%
BNY Mellon US Mid Cap Core Equity ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™